NIOX Group (NIOX.L) Stock Analysis & Winston Score

NIOX Group makes medical devices that help doctors diagnose and monitor asthma. Its main product is the NIOX VERO, a handheld device that measures a gas called nitric oxide in a patient's breath. High levels of this gas can signal airway inflammation, helping doctors decide whether a patient has asthma and how well their treatment is working. The company sells primarily to hospitals, clinics, and specialist respiratory doctors. NIOX makes money by selling both the devices and the disposable mouthpiece sensors that patients must use each time they are tested — this creates a recurring revenue stream from consumables. The company operates mainly in the United States, Europe, and parts of Asia, and its installed base of devices drives steady repeat purchases of those single-use sensors, which is a meaningful competitive advantage. The key growth driver is wider adoption of fractional exhaled nitric oxide testing as a standard step in asthma diagnosis, though reimbursement policies in different countries remain a risk to that expansion.